Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford Sells 1,817 Shares

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 1,817 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $14,299.79. Following the completion of the transaction, the chief operating officer now directly owns 21,367 shares in the company, valued at $168,158.29. This trade represents a 7.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kathleen Ford also recently made the following trade(s):

• On Monday, November 18th, Kathleen Ford sold 526 shares of Kura Oncology stock. The shares were sold at an average price of $16.03, for a total value of $8,431.78.

Kura Oncology Stock Performance

Shares of KURA stock opened at $7.77 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market cap of $604.20 million, a P/E ratio of -3.29 and a beta of 0.81. The firm’s 50 day moving average price is $9.23 and its 200-day moving average price is $15.69. Kura Oncology, Inc. has a one year low of $6.98 and a one year high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.01. During the same period last year, the firm earned ($0.50) EPS. As a group, equities research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Tuesday, November 19th. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Wedbush reiterated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a report on Monday, November 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.38.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the company. Suvretta Capital Management LLC increased its stake in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after purchasing an additional 583,155 shares during the period. Geode Capital Management LLC grew its holdings in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after purchasing an additional 41,535 shares in the last quarter. Franklin Resources Inc. increased its stake in Kura Oncology by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after buying an additional 23,113 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Kura Oncology by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock worth $12,212,000 after buying an additional 14,106 shares in the last quarter. Finally, Alethea Capital Management LLC boosted its position in Kura Oncology by 108.2% in the 3rd quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock valued at $10,816,000 after buying an additional 287,636 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.